Search details
1.
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
J Virol
; 95(19): e0068521, 2021 09 09.
Article
in English
| MEDLINE | ID: mdl-34287040
2.
Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules.
Proc Natl Acad Sci U S A
; 115(40): E9353-E9361, 2018 10 02.
Article
in English
| MEDLINE | ID: mdl-30213851
3.
The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.
Mol Immunol
; 139: 168-176, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34543843
4.
A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
Antiviral Res
; 194: 105147, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34375715
5.
Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.
Cell Rep
; 29(6): 1621-1632.e3, 2019 11 05.
Article
in English
| MEDLINE | ID: mdl-31693900
6.
TAPBPR mediates peptide dissociation from MHC class I using a leucine lever.
Elife
; 72018 11 28.
Article
in English
| MEDLINE | ID: mdl-30484775
Results
1 -
6
de 6
1
Next >
>>